Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date

References

• Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabet Res Clin Pract. 2022 Jan;183:109119.
   PubMed Web of Science ®Google Scholar
• Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease [journal article]. Diabetologia. 2013 Apr 1;56(4):686–695. doi: 10.1007/s00125-012-2817-5
   PubMed Web of Science ®Google Scholar
• Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022 Apr;10(4):284–296. doi: 10.1016/S2213-8587(22)00003-1
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacotherapy of ‘treatment resistant’ type 2 diabetes. Expert Opin Pharmacother. 2017 Apr;18(5):503–515. doi: 10.1080/14656566.2017.1297424
   PubMed Web of Science ®Google Scholar
• ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of Care in diabetes—2023. Diabetes Care. 2022;46(Supplement_1):S140–S157. doi: 10.2337/dc23-S009.
   Google Scholar
• Colagiuri S, Matthews D, Leiter LA, et al. The place of gliclazide MR in the evolving type 2 diabetes landscape: a comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes Res Clin Pract. 2018 [2018/Sep/1/];143:1–14.
   PubMed Web of Science ®Google Scholar
• Maloney A, Rosenstock J, Fonseca V. A Model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses. Clin Pharmacol Ther. 2019 May;105(5):1213–1223. doi: 10.1002/cpt.1307.
   PubMed Web of Science ®Google Scholar
• Dornhorst A. Insulinotropic meglitinide analogues. Lancet. 2001 Nov 17;358(9294):1709–1716. doi: 10.1016/S0140-6736(01)06715-0
   PubMed Web of Science ®Google Scholar
• Hedrington MS, Davis SN. Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.Expert Opin Pharmacother. 2019 [2019/Dec/12];20(18):2229–2235. DOI:10.1080/14656566.2019.1672660.
   PubMed Web of Science ®Google Scholar
• Gale EAM. Troglitazone: the lesson that nobody learned?Diabetologia. 2006 [2006/Jan/1];49(1):1–6. DOI:10.1007/s00125-005-0074-6.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457–2471. doi: 10.1056/NEJMoa072761
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007 Sep 12;298(10):1189–1195. doi: 10.1001/jama.298.10.1189
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005 Oct 8;366(9493):1279–1289. doi: 10.1016/S0140-6736(05)67528-9
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Chan P, Lam CWK. An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2022 Jan;23(1):29–42. doi: 10.1080/14656566.2021.1985465.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Guidance for Industry. Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes, Dec 2008. Available from www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 1 May 2023.
   Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013;369(14):1317–1326. doi: 10.1056/NEJMoa1307684
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular Outcomes in type 2 diabetes. N Engl J Med. 2019 Jan 24;380(4):347–357. doi: 10.1056/NEJMoa1812389
   PubMed Web of Science ®Google Scholar
• Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020 Oct 8;383(15):1425–1435. doi: 10.1056/NEJMoa2004967
   PubMed Web of Science ®Google Scholar
• Toyama T, Neuen BL, Jun M, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diab Obes Metab. 2019 May;21(5):1237–1250. doi: 10.1111/dom.13648
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311–322. doi: 10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular Outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi: 10.1056/NEJMoa1607141
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 [2019/Jul/13/];394(10193):121–130. doi: 10.1016/S0140-6736(19)31149-3
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018 [2018/Oct/27];392(10157):1519–1529. doi: 10.1016/S0140-6736(18)32261-X
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257. doi: 10.1056/NEJMoa1509225
   PubMed Web of Science ®Google Scholar
• Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly Exenatide on cardiovascular Outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–1239. doi: 10.1056/NEJMoa1612917
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular Outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851. doi: 10.1056/NEJMoa1901118
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019 Apr 23;139(17):2022–2031. doi: 10.1161/CIRCULATIONAHA.118.038868
   PubMed Web of Science ®Google Scholar
• Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metabol. 2018 [2018/Dec/1];18:3–14.
   PubMed Web of Science ®Google Scholar
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. doi: 10.1056/NEJMoa2206038
   PubMed Web of Science ®Google Scholar
• FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes. May 13, 2022. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes. Accessed 20 Jun 2023.
   Google Scholar
• Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetologia. 2022 Dec;65(12):1925–1966. doi: 10.1007/s00125-022-05787-2
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Chuck L, Gonzalez-Ortiz M, et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naive type 2 diabetes. Diabetes Care. 2016 Mar;39(3):353–362.doi: 10.2337/dc15-1736
   PubMed Web of Science ®Google Scholar
• Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013 Dec;56(12):2582–2592. doi: 10.1007/s00125-013-3039-1
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013 Sep 14;382(9896): 941–950. doi: 10.1016/S0140-6736(13)60683-2.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015 Mar;38(3):355–364. doi: 10.2337/dc13-2762
   PubMed Web of Science ®Google Scholar
• INVOKAMET® XR (canagliflozin and metformin hydrochloride extended-release) tablets, for oral use [package insert]. Titusville: Janssen Pharmaceuticals; 2016. https://www.janssenlabels.com/package-insert/product-patient-information/INVOKAMET+XR-medication-guide.pdf
   Google Scholar
• Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diab Obes Metab. 2012 Jan;14(1):83–90. doi: 10.1111/j.1463-1326.2011.01517.x
   PubMed Web of Science ®Google Scholar
• Polidori D, Sha S, Mudaliar S, et al. Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study. Diabetes Care. 2013;36(8):2154–2161. doi: 10.2337/dc12-2391
   PubMed Web of Science ®Google Scholar
• Koufakis T, Doumas M, Zebekakis P, et al. Dual sodium-glucose cotransporter (SGLT) 1/2 versus pure SGLT2 inhibitors: two distinct drug categories or one class with multiple faces? Expert Opin Pharmacother. 2022 [2022/Sep/2];23(13):1497–1502. doi: 10.1080/14656566.2022.2113385
   PubMed Web of Science ®Google Scholar
• Chow E, Yang A, Chung CHL, et al. A clinical perspective of the multifaceted mechanism of metformin in diabetes, infections, cognitive dysfunction, and cancer. Pharmaceuticals (Basel). 2022 Apr 2;15(4):442. doi: 10.3390/ph15040442
   PubMedGoogle Scholar
• LaMoia TE, Shulman GI. Cellular and molecular mechanisms of metformin action. Endocr Rev. 2021 Jan 28;42(1):77–96. doi: 10.1210/endrev/bnaa023
   PubMed Web of Science ®Google Scholar
• Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nature Med. 2017 [2017/Jul/1];23(7):850–858. doi: 10.1038/nm.4345
   PubMed Web of Science ®Google Scholar
• Davidson JA, Sloan L. Fixed-dose combination of canagliflozin and metformin for the treatment of type 2 diabetes: an overview. Adv Ther. 2017 Jan;34(1):41–59. doi: 10.1007/s12325-016-0434-2.
   PubMed Web of Science ®Google Scholar
• Fala L. Invokamet (canagliflozin plus metformin HCl): first fixed-dose combination with an SGLT2 inhibitor approved for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):70–74.
   PubMedGoogle Scholar
• Fleming JW, Fleming LW, Davis CS. Fixed-dose combinations in type 2 diabetes - role of the canagliflozin metformin combination. Diabetes Metab Syndr Obes. 2015;8:287–294. doi: 10.2147/DMSO.S69282
   PubMed Web of Science ®Google Scholar
• Devineni D, Polidori D. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. Clin Pharmacokinet. 2015 Oct;54(10):1027–1041. doi: 10.1007/s40262-015-0285-z.
   PubMed Web of Science ®Google Scholar
• Mamidi RN, Cuyckens F, Chen J, et al. Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans. Drug Metab Dispos. 2014 May;42(5):903–916. doi: 10.1124/dmd.113.056440
   PubMed Web of Science ®Google Scholar
• Chan P, Shao L, Tomlinson B, et al. Metformin transporter pharmacogenomics: insights into drug disposition-where are we now? Expert Opin Drug Metab Toxicol. 2018 Nov;14(11):1149–1159. doi: 10.1080/17425255.2018.1541981
   PubMed Web of Science ®Google Scholar
• Devineni D, Curtin C, Ariyawansa J, et al. Bioequivalence of canagliflozin/metformin immediate release fixed-dose combination tablets compared with concomitant administration of single components of canagliflozin and metformin in healthy fed participants. J Bioequivalence Bioavailability. 2014;6(6):164–173. doi: 10.4172/jbb.1000199
   Google Scholar
• Murphy J, Wang SS, Stieltjes H, et al. Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants. Int J Clin Pharmacol Ther. 2015 Mar;53(3):256–264. doi: 10.5414/CP202233
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal Outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/NEJMoa1811744
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Desai M, Jardine M, et al. Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. J Am Soc Nephrol. 2017;28(1):368–375. doi: 10.1681/ASN.2016030278
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. [1998 Sep 12];352(9131):854–865. doi: 10.1016/S0140-6736(98)07037-8
   PubMed Web of Science ®Google Scholar
• Drzewoski J, Hanefeld M. The Current and potential therapeutic use of metformin—the good old drug. Pharmaceuticals. 2021;14(2):122. doi: 10.3390/ph14020122
   Web of Science ®Google Scholar
• Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diab Obes Metab. 2014 May;16(5):467–477. doi: 10.1111/dom.12273
   PubMed Web of Science ®Google Scholar
• Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013 Dec;67(12):1267–1282. doi: 10.1111/ijcp.12322
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013 Sep;36(9):2508–2515. doi: 10.2337/dc12-2491
   PubMed Web of Science ®Google Scholar
• Yuan Z, DeFalco FJ, Ryan PB, et al. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study. Diabetes Obesity Metab. 2018;20(3):582–589. doi: 10.1111/dom.13115
   PubMed Web of Science ®Google Scholar
• Cowart K, Coon S, Carris NW. A review of the safety and efficacy of bexagliflozin for the management of type 2 diabetes. Ann Pharmacother. 2023 Aug;11:10600280231190443. doi: 10.1177/10600280231190443
   Google Scholar
• Rossing P, Caramori ML, Chan JCN, et al. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5):S1–S127. doi: 10.1016/j.kint.2022.06.008
   PubMed Web of Science ®Google Scholar
• Abrilla AA, Pajes A, Jimeno CA. Metformin extended-release versus metformin immediate-release for adults with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabet Res Clin Pract. 2021 Aug;178:108824. doi: 10.1016/j.diabres.2021.108824
   PubMed Web of Science ®Google Scholar
• Aggarwal N, Singla A, Mathieu C, et al. Metformin extended-release versus immediate-release: an international, randomized, double-blind, head-to-head trial in pharmacotherapy-naive patients with type 2 diabetes. Diab Obes Metab. 2018 Feb;20(2):463–467. doi: 10.1111/dom.13104
   PubMed Web of Science ®Google Scholar
• Hameed M, Khan K, Salman S, et al. Dose comparison and side effect profile of metformin extended release versus metformin immediate release. J Ayub Med Coll Abbottabad. 2017 Apr;29(2):225–229.
   PubMedGoogle Scholar
• FDA approves invokamet XR (canagliflozin/metformin hydrochloride extended-release) for the treatment of adults with type 2 diabetes. Sep 21, 2016. Available at: https://www.drugs.com/newdrugs/fda-approves-invokamet-xr-canagliflozin-metformin-hydrochloride-extended-release-adults-type-2-4433.html. Accessed 20 Jul 2023.
   Google Scholar
• Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022 Sep 22;387(12):1089–1098. doi: 10.1056/NEJMoa2206286
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021 Oct 14;385(16):1451–1461. doi: 10.1056/NEJMoa2107038
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013 Oct;34(38):2940–2948. doi: 10.1093/eurheartj/eht295
   PubMed Web of Science ®Google Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010 Feb;55(2):399–407. doi: 10.1161/HYPERTENSIONAHA.109.139816.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018 [2018 Sep 1];39(33):3021–3104. doi: 10.1093/eurheartj/ehy339
   PubMed Web of Science ®Google Scholar
• Unger T, Borghi C, Charchar F, et al. International Society of hypertension Global hypertension practice guidelines. Hypertension. 2020 [2020 Jun];75(6):1334–1357. doi: 10.1161/HYPERTENSIONAHA.120.15026
   PubMed Web of Science ®Google Scholar
• Vijayakumar TM, Jayram J, Meghana Cheekireddy V, et al. Safety, efficacy, and bioavailability of fixed-dose combinations in type 2 diabetes mellitus: a systematic updated review. Curr Ther Res Clin Exp. 2017;84:4–9. doi: 10.1016/j.curtheres.2017.01.005
   PubMed Web of Science ®Google Scholar
• Lautsch D, Alsumali A, McLeod E, et al. Comparative efficacy of dual and single initiation of add-on oral antihyperglycemic agents in type 2 diabetes uncontrolled on metformin alone: a systematic Literature review and network meta-analysis. Diabetes Therapy. 2021 [2021/Jan/1];12(1):389–418. doi: 10.1007/s13300-020-00975-y
   PubMed Web of Science ®Google Scholar
• Matthews DR, Paldánius PM, Proot P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019 [2019/Oct/26];394(10208):1519–1529. doi: 10.1016/S0140-6736(19)32131-2
   PubMed Web of Science ®Google Scholar
• Paul SK, Bhatt DL, Montvida O. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study. Eur Heart J. 2020;42(18):1728–1738. doi: 10.1093/eurheartj/ehaa956
   Web of Science ®Google Scholar